Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial

Documenti analoghi

• Who owns that blood? Recontacting donors with results from genetic testing after allogeneic hematopoietic cell transplantation
  di: Mirjam E. Belderbos, et al.
  Pubblicazione: (2025)
• Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studies
  di: Coen R. Veenstra, et al.
  Pubblicazione: (2026)
• Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
  di: Baptiste Le Calvez, et al.
  Pubblicazione: (2024)
• Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
  di: Konradin F. Müskens, et al.
  Pubblicazione: (2024)
• Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
  di: Marion Larue, et al.
  Pubblicazione: (2024)